Qi, Ming

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 1,522

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,045

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., Goldschmidt, H., et al. (2020) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 291

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

San-Miguel, J., Avet-Loiseau, H., Paiva, B., Kumar, S., Dimopoulos, M. A., Facon, T., Mateos, M.-V., Touzeau, C., Jakubowiak, A., Usmani, S. Z., et al. (2022) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 153

Risk of fatal arrhythmic events in long QT syndrome patients after syncope

Jons, C., Moss, A. J., Goldenberg, I., Liu, J., McNitt, S., Zareba, W., Qi, M., & Robinson, J. L. (2010) · Journal of the American College of Cardiology

Cardiac electrophysiology and arrhythmiasCardiovascular Syncope and Autonomic Disorders

Cited by 138

Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome

Liu, J. F., Jons, C., Moss, A. J., McNitt, S., Peterson, D. R., Qi, M., Zareba, W., Robinson, J. L., Barsheshet, A., Ackerman, M. J., et al. (2011) · Journal of the American College of Cardiology

Cardiac electrophysiology and arrhythmiasCardiovascular Syncope and Autonomic Disorders

Cited by 126

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 102

Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (Anti-IL6 Monoclonal Antibody) in patients with multicentric castleman disease

Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., et al. (2015) · Clinical Cancer Research

Viral-associated cancers and disordersAutoimmune and Inflammatory Disorders Research

Cited by 97

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 50

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

Mateos, M.-V., Nahi, H., Legiec, W., Grosicki, S., Vorobyev, V., Spicka, I., Hungria, V. T., Korenkova, S., Bahlis, N. J., Flogegard, M., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 25

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Bahlis, N., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Ho, P. J., Kim, K., Takezako, N., Moreau, P., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 21

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Mateos, M.-V., Sonneveld, P., Hungria, V. T. M., Nooka, A. K., Estell, J., Barreto, W. G., Corradini, P., Min, C.-K., Medvedova, E., Weisel, K., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 10